Skip to content
DataLookout
Menu

ClinicalTrials.gov term: Myelodysplastic-Myeloproliferative Diseases

MDS/MPN Overlap clinical trials

Get alerts when MDS/MPN Overlap trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

12 trials changed in the last 30 days: 2 stopped, 3 with notable changes, 7 with minor changes only.

  1. Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended Thomas Jefferson UniversityPhase 2 NCT05031897
  2. Notable: APTBCy · Optimization of Post-transplantation Benadamustine and Cyclophosphamide · High-risk Myeloid Malignancies and a Partially Mismatched Donor Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027 St. Petersburg State Pavlov Medical UniversityPhase 2 NCT07238712
  3. Notable: Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood · Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Primary and study completion pushed from Dec 31, 2030 to Dec 31, 2032 PedAL BCU, LLCPhase 1/2 NCT04726241
  4. Minor: Clofarabine and Melphalan Before Donor Stem Cell Transplant · Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Study completion pushed from Sep 21, 2026 to Aug 23, 2027 City of Hope Medical CenterPhase 2 NCT01885689
  5. Minor: Ropeginterferon Alfa-2b · Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Primary completion pushed from Sep 30, 2031 to Jan 30, 2032 Jonsson Comprehensive Cancer CenterPhase 2 NCT07468916
  6. Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated M.D. Anderson Cancer CenterPhase 1 NCT02530034
  7. Minor: Trametinib · Relapsed or Refractory Juvenile Myelomonocytic Leukemia Study completion pushed from Oct 3, 2026 to Oct 14, 2027 National Cancer Institute (NCI)Phase 2 NCT03190915
  8. Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026 National Cancer Institute (NCI)Phase 1 NCT06904066
  9. Minor: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at · Hemoblastosis Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Active, Not Recruiting Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 3 NCT05515029
  10. Notable: Therapeutic RSK1 Targeting in Myeloid Malignancies Enrollment increased: 18 → 30 participants Washington University School of MedicinePhase 1 NCT07379125
  11. Minor: MYELOMATCH · Screening Study to Assign · Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Trial sites expanded: 354 → 358 locations National Cancer Institute (NCI)Phase 2 NCT05564390
  12. Minor: CONCERTO · Cobimetinib in Newly Diagnosed or HMA-treated CMML · RAS Pathway Mutations Study completion pushed from Aug 2026 to Oct 2026 University of UtahPhase 2 NCT04409639
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-03 NCT07914556 Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers Mabwell (Shanghai) Bioscience Co., Ltd. new Phase 1

Active trials by phase

Early Phase 1
3
Phase 1
34
Phase 1/2
27
Phase 2
56
Phase 2/3
2
Phase 3
4
Not charted: 27 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when MDS/MPN Overlap trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials